On this page
MYL2
myosin light chain 2
MYL2 encodes a regulatory component of cardiac muscle myosin, with pathogenic variants causing inherited heart muscle disease recognised in NHS screening programmes. The MYL2 gene provides instructions for making the regulatory light chain of ventricular myosin, a protein essential for heart muscle contraction.
MYL2 is located on the long (q) arm of chromosome 12, at band 12q24.11. Arm ratio per GRCh38 - banding schematic.
Explore chromosome 12 in the library →Overview
MYL2 encodes myosin light chain 2, a regulatory protein that modulates the contractile machinery of cardiac muscle cells. The gene resides on chromosome 12 and produces a 166-amino acid protein that binds calcium and integrates mechanical and biochemical signals during each heartbeat. Pathogenic variants in MYL2 alter the protein's structure or calcium-binding properties, leading to inherited heart muscle disorders that typically present in childhood or adulthood.
The clinical significance of MYL2 has been recognised through its inclusion on the ACMG Secondary Findings list version 3.2, reflecting the medical actionability of identifying pathogenic variants before symptoms appear. In the UK, MYL2 appears as a green gene on multiple NHS PanelApp panels for cardiomyopathy, meaning there is robust evidence supporting its role in disease and its use in clinical diagnostic testing. Carriers of pathogenic MYL2 variants may benefit from cardiac surveillance and family cascade testing to identify at-risk relatives.
What the gene does
The MYL2 protein functions as the regulatory light chain of cardiac ventricular myosin, forming part of the molecular motor that generates force during muscle contraction. Each myosin molecule comprises two heavy chains and four light chains - two essential and two regulatory. MYL2 sits at the lever-arm region of the myosin head, where it modulates the mechanics of the power stroke that drives sarcomere shortening and produces the contractile force necessary for ejecting blood from the ventricles.
Calcium binding to MYL2's EF-hand domains triggers conformational changes that influence myosin's interaction with actin filaments. When intracellular calcium levels rise during systole, calcium ions occupy specific binding pockets within the protein, altering the angle and rigidity of the myosin lever arm. This calcium-dependent regulation allows the heart to adjust contractile strength in response to physiological demand, coordinating the timing and magnitude of each contraction cycle.
MYL2 also participates in phosphorylation-based signalling pathways that fine-tune cardiac performance. Kinases can add phosphate groups to specific serine residues on the regulatory light chain, modifying the protein's shape and thereby influencing the rate of cross-bridge cycling between myosin and actin. This post-translational modification provides an additional layer of control over contractility, enabling the heart to respond dynamically to exercise, stress, or changes in autonomic tone. The protein's role extends beyond simple force generation to encompass mechanosensing and adaptive responses that maintain cardiac output across varying physiological states.
Video: Genetics 101
Chromosome location
MYL2 is located on the long arm of chromosome 12 at cytogenetic band 12q24.11. The gene spans approximately 7 kilobases of genomic DNA and contains seven exons that encode the 166-amino acid regulatory light chain protein. This chromosomal region has been mapped through linkage studies and comparative genomic analyses, confirming its conservation across mammalian species.
The gene's position at 12q24.11 places it within a region containing several other genes involved in cardiovascular and metabolic function. The compact structure of MYL2, with relatively few exons and short introns, facilitates efficient transcription and splicing in cardiac myocytes, where high levels of the protein are required to support continuous contractile activity throughout life.
Protein structure
The canonical MYL2 isoform comprises 166 amino acids organised into a structure dominated by three calcium-binding EF-hand motifs. EF-hand 1 spans amino acids 24 to 59, EF-hand 2 occupies positions 94 to 129, and EF-hand 3 extends from residue 130 to 165. Each EF-hand consists of a helix-loop-helix architecture in which the loop region coordinates a calcium ion through conserved aspartate and glutamate residues. (These boundaries have been verified against UniProt entry P10916.)
The three EF-hands are arranged in a compact globular fold that positions the calcium-binding loops on one face of the molecule, allowing coordinated metal binding and cooperative conformational transitions. The first and second EF-hands typically exhibit higher affinity for calcium and undergo more pronounced structural rearrangement upon ion binding, whereas the third EF-hand contributes to overall protein stability and may modulate the responsiveness of the upstream domains.
This domain organisation enables MYL2 to function as a calcium sensor and mechanical transducer. The binding of calcium ions induces a shift in the relative orientation of the helical segments, which propagates through the lever arm of the myosin molecule and influences the force and velocity of muscle contraction. Pathogenic variants often cluster within or near the EF-hand regions, disrupting calcium coordination or destabilising the protein fold and thereby impairing the regulatory capacity of the light chain.
Key variants
Pathogenic variants in MYL2 encompass missense substitutions, small deletions, and insertions that alter protein structure or calcium-binding affinity. Missense changes are the most frequently reported class of pathogenic variant, often affecting residues within the EF-hand domains or at sites critical for interaction with the myosin heavy chain. These substitutions can increase or decrease calcium sensitivity, shift the force-velocity relationship of cardiac myosin, or destabilise the protein fold, each mechanism leading to altered contractile dynamics.
The variant landscape includes both well-characterised founder mutations in specific populations and private variants unique to individual families. Genotype-phenotype correlations remain an active area of research, with some variants associated with earlier onset or more severe cardiac hypertrophy, while others present with milder or later-onset disease. Functional studies in model systems have demonstrated that different MYL2 variants can produce distinct effects on calcium handling, cross-bridge kinetics, and energetic efficiency, underscoring the molecular heterogeneity of MYL2-related cardiomyopathy.
Sample of pathogenic variants
10 pathogenic / likely-pathogenic variants from ClinVar, ranked by review status (expert-panel-reviewed first). This is a sample; recurrent founder variants in a specific population may not appear here - see the full ClinVar listing via the link above.
| Variant (HGVS) | Protein change | Classification | Evidence | Associated condition |
|---|---|---|---|---|
c.173G>A | p.Arg58Gln | Pathogenic/Likely pathogenic | ★★☆☆ | MYL2-related disorder |
c.239C>A | p.Thr80Asn | Pathogenic/Likely pathogenic | ★★☆☆ | MYL2-related disorder |
c.497A>T | p.Asp166Val | Pathogenic/Likely pathogenic | ★★☆☆ | Cardiovascular phenotype |
c.52T>C | p.Phe18Leu | Pathogenic/Likely pathogenic | ★★☆☆ | Hypertrophic cardiomyopathy 10 |
c.64G>A | p.Glu22Lys | Pathogenic/Likely pathogenic | ★★☆☆ | Hypertrophic cardiomyopathy 10 |
g.(?_110910819)_(110911175_?)del | - | Pathogenic | ★☆☆☆ | Hypertrophic cardiomyopathy 10 |
c.286G>A | p.Glu96Lys | Pathogenic/Likely pathogenic | - | not provided |
c.473T>C | p.Ile158Thr | Pathogenic | - | Congenital heart disease |
c.485G>A | p.Gly162Glu | Likely pathogenic | ★★★☆ | Hypertrophic cardiomyopathy |
c.173G>T | p.Arg58Leu | Likely pathogenic | ★★☆☆ | Hypertrophic cardiomyopathy 10 |
Evidence stars indicate ClinVar review status. Individual variant interpretation should always be performed by a qualified clinical laboratory - many variants remain classified as Variants of Uncertain Significance (VUS) pending more research.
Associated conditions
Pathogenic variants in MYL2 cause inherited forms of hypertrophic cardiomyopathy and congenital myopathy, both recognised in NHS clinical pathways. Hypertrophic cardiomyopathy is characterised by abnormal thickening of the heart muscle, particularly the interventricular septum, which can obstruct blood flow and increase the risk of arrhythmia and sudden cardiac death. Symptoms may include shortness of breath, chest pain, palpitations, and exercise intolerance, though some individuals remain asymptomatic for years.
Congenital myopathy refers to a group of muscle disorders present from birth or early childhood, often manifesting as muscle weakness, delayed motor milestones, and respiratory complications. The phenotypic spectrum associated with MYL2 variants can overlap between cardiac and skeletal muscle involvement, reflecting the shared contractile machinery in both tissue types. Disease penetrance and severity vary among families and even within the same pedigree, influenced by genetic modifiers, environmental factors, and the specific functional consequence of the underlying variant.
No disease links recorded for this gene in our reference set.
Inheritance pattern
Conditions caused by pathogenic MYL2 variants typically follow autosomal dominant inheritance.
Each child has a 50% chance of inheriting the pathogenic variant, regardless of sex.
UK clinical status
MYL2 has been designated a green gene on NHS England PanelApp panels for Hypertrophic Cardiomyopathy, Paediatric or Syndromic Cardiomyopathy, and Congenital Myopathy. Green classification indicates that there is robust clinical and research evidence supporting the use of MYL2 testing in diagnostic genomic analysis for patients with these phenotypes.
These panel memberships guide genomic testing strategy within the NHS Genomic Medicine Service, ensuring that MYL2 is included in diagnostic gene panels for appropriate clinical presentations. Patients undergoing cardiac genetic testing for unexplained ventricular hypertrophy or paediatric cardiomyopathy will typically have MYL2 sequenced as part of a multi-gene panel, with pathogenic variants triggering cascade testing in at-risk family members and informing clinical management decisions.
Sources: NHS GMS PanelApp · Genomics England PanelApp · NHS National Genomic Test Directory
Diet & lifestyle considerations
For individuals with pathogenic MYL2 variants, lifestyle recommendations centre on cardiovascular health and avoidance of activities that may increase the risk of arrhythmia or sudden cardiac events. Research in hypertrophic cardiomyopathy populations suggests that moderate-intensity aerobic exercise may be safe for some individuals, though competitive or high-intensity sports are generally discouraged due to the increased haemodynamic stress they impose on an already abnormal ventricle. Clinical guidelines emphasise the importance of individualised risk assessment, with exercise recommendations tailored to the degree of ventricular hypertrophy, presence of outflow obstruction, and history of arrhythmia.
Maintaining a balanced diet with attention to cardiovascular risk factors such as hypertension, dyslipidaemia, and obesity may support overall cardiac function, though no specific dietary pattern has been proven to alter disease progression in MYL2-related cardiomyopathy. Some cardiologists advise limiting caffeine and alcohol intake, as both substances can provoke arrhythmias in susceptible individuals. Hydration status and electrolyte balance also warrant attention, particularly during illness or periods of increased physical demand.
Psychological wellbeing and stress management are relevant considerations, given that autonomic arousal can influence heart rate and contractility. While no evidence directly links stress reduction to improved outcomes in MYL2 carriers, general principles of cardiovascular health support the value of adequate sleep, mental health support, and avoidance of stimulant medications where feasible. Any lifestyle modification should be discussed with a healthcare provider familiar with the individual's specific cardiac phenotype and risk profile.
Supplement considerations
There is no conclusive evidence that any dietary supplement prevents or mitigates cardiomyopathy in individuals with MYL2 variants. Some observational studies have explored the potential role of coenzyme Q10, L-carnitine, and omega-3 fatty acids in supporting mitochondrial function and reducing oxidative stress in heart muscle, but robust clinical trial data demonstrating benefit in genetic cardiomyopathy remain limited. The theoretical rationale for these supplements rests on their involvement in energy metabolism and membrane stability, processes that may be compromised in hypertrophied or failing myocardium.
Magnesium and potassium supplementation are sometimes considered in the context of arrhythmia prevention, as deficiencies in these electrolytes can increase susceptibility to abnormal heart rhythms. However, supplementation should only be undertaken if a documented deficiency exists or if clinically indicated, as excessive intake can itself cause adverse cardiac effects. Routine use of electrolyte supplements without medical guidance is not recommended.
Individuals considering any supplement should consult a healthcare provider before starting, particularly if they are taking prescribed cardiac medications such as beta-blockers, calcium channel blockers, or antiarrhythmic drugs. Supplement-drug interactions can alter medication efficacy or increase the risk of side effects, and any intervention should be integrated into a comprehensive care plan overseen by a specialist familiar with inherited cardiac disease.
Frequently asked questions
What does the MYL2 gene do?
MYL2 encodes the regulatory light chain of cardiac myosin, a protein that modulates heart muscle contraction by binding calcium and influencing the mechanical properties of the myosin motor. It plays a central role in coordinating the force and timing of each heartbeat.
How is MYL2-related cardiomyopathy inherited?
MYL2-related conditions follow an autosomal dominant pattern of inheritance, meaning a single pathogenic variant inherited from one parent is sufficient to cause disease. Each child of an affected individual has a 50% chance of inheriting the variant.
Can MYL2 variants cause symptoms in childhood?
Yes, some MYL2 variants are associated with early-onset cardiomyopathy or congenital myopathy presenting in infancy or childhood. However, many individuals remain asymptomatic until adolescence or adulthood, and penetrance can be incomplete even within the same family.
Is genetic testing for MYL2 available on the NHS?
Yes, MYL2 is included on NHS England PanelApp green gene lists for hypertrophic cardiomyopathy, paediatric cardiomyopathy, and congenital myopathy. Patients meeting clinical criteria for these conditions can access diagnostic genetic testing through the NHS Genomic Medicine Service.
What is the ACMG Secondary Findings designation for MYL2?
MYL2 appears on the American College of Medical Genetics and Genomics Secondary Findings list version 3.2, with strong evidence for medical actionability. This designation indicates that identifying pathogenic MYL2 variants incidentally during genome or exome sequencing has clear medical benefit, as surveillance and intervention can reduce morbidity and mortality.
Should I avoid exercise if I carry a pathogenic MYL2 variant?
Exercise recommendations must be individualised based on cardiac imaging, arrhythmia risk, and symptom status. Many individuals with MYL2-related cardiomyopathy can engage in moderate-intensity activity safely, but competitive sports and high-intensity training are typically discouraged. Discuss your specific situation with a cardiologist experienced in inherited heart disease.